Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

Abstract

Psoriasis is a recurring systemic disease that can be treated with biologics to some effect. However, precisely targeting inflammatory mediators may disrupt immune system homeostasis and lead to new conditions. Here, we report a case of psoriasiform dermatitis (PsoD) caused by IL-17 inhibitors (IL-17i) namely secukinumab treatment for psoriasis. This case proposes an effective use of Janus kinase inhibitor (JAKi) tofacitinib to confront lesions induced by IL-17i. This is the first case report of PsoD caused by secukinumab treated with tofacitinib.

Keywords:

• tofacitinib
• Janus kinase inhibitor
• psoriasiform dermatitis
• Th1-Th2 balance
• IL-17 inhibitors

Abbreviations

PsoD, psoriasiform dermatitis; IL-17i, IL-17 inhibitors; JAKi, Janus kinase inhibitor; UV, Ultraviolet; Th cell, T helper cell; JAK/STAT, Janus kinase/signal transducer and activator of transcription; Tregs, regulatory T cells.

Data Sharing Statement

The data that support the findings of this study are available from the corresponding author (Pingsheng Hao) upon request.

Ethical Approval and Consent to Participate

The study was approved by the Ethics Committee of Hospital of Chengdu University of Traditional Chinese Medicine. Written informed consent was obtained from the patient for the publication of all the images and data included in this article. Ethical review and approval were not required to publish the case details in accordance with the institutional requirements.

Consent to Publish

The patient has consented to the submission of the case report to the journal.

Acknowledgments

First and foremost, thanks to the Sichuan Provincial Health Commission for providing financial support. Secondly, I would like to thank Dr. Tianhao Li for his guidance. Finally, I would like to pay the highest respect to my mentor, Pingsheng Hao, for his excellent advice and respectful teaching.

Author Contributions

Pingsheng Hao serves as the primary corresponding author for this paper, while Tianhao Li acts as the secondary corresponding author. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was supported by the Program of Health Commission of Sichuan Province (Grant No. Chuan-2021-505). And preparation and development of medicated bath Wupi effervescent tablets for senile skin pruritus.